Age-associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow

Annals of Surgery

Volumn 258, Issue 1, 2013, Pages 184-191

  Rogers, Natasha M ^a   Roberts, David D ^b   Isenberg, Jeffrey S ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Aging; Blood flow; CD47; Nitric oxide; Skin; Thermal stress; Thrombospondin 1; Wound healing

Indexed keywords

CD47 ANTIGEN; CYCLIC GMP; NITRIC OXIDE; THROMBOSPONDIN 1;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; HYPOTHESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN BLOOD FLOW; TEMPERATURE; TEMPERATURE STRESS; WILD TYPE;

AGE FACTORS; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD47; BLOOD PRESSURE; CELL MEMBRANE; CYCLIC GMP; LASER-DOPPLER FLOWMETRY; MALE; MICE; MICE, INBRED C57BL; NITRIC OXIDE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SKIN; TEMPERATURE; THROMBOSPONDIN 1;

EID: 84879073816     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e31827e52e1     Document Type: Article

References (56)

1. Charkoudian N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc. 2003;78:603-612.
2. Wallin BG. Neural control of human skin blood flow. J Auton Nerv Syst. 1990;30:S185-S190.
3. Charkoudian N, Johnson JM. Female reproductive hormones and thermoregulatory control of skin blood flow. Exerc Sport Sci Rev. 2000;28:108-112.
4. Heistad DD, Abboud FM. Factors that influence blood flow in skeletal muscle and skin. Anesthesiology. 1974;41:139-156.
5. Belcaro G, Vasdekis S, Rulo A, et al. Evaluation of skin blood flow and venoarteriolar response in patients with diabetes and peripheral vascular disease by laser Doppler flowmetry. Angiology. 1989;40:953-957.
6. Le Roy EC, Downey JA, Cannon PJ. Skin capillary blood flow in scleroderma. J Clin Invest. 1971;50:930-939.
7. Salsano F, Letizia C, Proietti M, et al. Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long termtreatment of patients with sclerodermic Raynauds phenomenon. Int J Immunopathol Pharmacol. 2005;18:761-770.
8. Strigini L, Ryan T. Wound healing in elderly human skin. Clin Dermatol. 1996;14:197-206.
9. Holowatz LA, Kenney WL. Peripheral mechanisms of thermoregulatory control of skin blood flow in aged humans. J Appl Physiol. 2010;109:1538-1544.
10. Toba K, Ouchi Y, Akishita M, et al. Improved skin blood flow and cutaneous temperature in the foot of a patient with arteriosclerosis obliterans by vasopressin V1 antagonist (OPC21268). A case report. Angiology. 1995;46:1027-1033.
11. Herrick AL, Gush RJ, Tully M, et al. A controlled trial of the effect of topical glyceryl trinitrate on skin blood flow and skin elasticity in scleroderma. Ann Rheum Dis. 1994;53:212.
12. Warren JB. Nitric oxide and human skin blood flow responses to acetylcholine and ultraviolet light. FASEB J. 1994;8:247-251.
13. Sokolnicki LA, Strom NA, Roberts SK, et al. Skin blood flow and nitric oxide during body heating in type 2 diabetesmellitus. J Appl Physiol. 2009;106:566-570.
14. Isenberg JS, Ridnour LA, Espey MG, et al. Nitric oxide in wound-healing. Microsurgery. 2005;25:442-451.
15. Luo JD, Chen AF. Nitric oxide: a newly discovered function on wound healing. Acta Pharmacol Sin. 2005;26:259-264.
16. Perez AC, Khawaja AM, Page CP, et al. Persistence of effects of nitric oxide synthase inhibitors: comparisons on blood flowand plasma exudation in guinea pig skin. Eur J Pharmacol. 1997;330:241-246.
17. Sigaudo-Roussel D, Demiot C, Fromy B, et al. Early endothelial dysfunction severely impairs skin blood flow response to local pressure application in streptozotocin-induced diabetic mice. Diabetes. 2004;53:1564-1569.
18. Gribbe O, Samuelson UE, Wiklund NP. Effects of nitric oxide synthase inhibition on blood flow and survival in experimental skin flaps. J Plast Reconstr Aesthet Surg. 2007;60:287-293.
19. Yan X, Zeng B, Chai Y, et al. Improvement of blood flow, expression of nitric oxide, and vascular endothelial growth factor by low-energy shockwave therapy in random-pattern skin flap model. Ann Plast Surg. 2008;61:646-653.
20. Gribbe O, Gustafsson LE, Wiklund NP. Transdermally administered nitric oxide by application of acidified nitrite increases blood flow in rat epigastric island skin flaps. Eur J Pharmacol. 2008;578:51-56.
21. Isenberg JS, Hyodo F, Pappan LK, et al. Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol. 2007;27:2582-2588.
22. Coffman JD. Effects of endothelium-derived nitric oxide on skin and digital blood flow in humans. Am J Physiol. 1994;267:H2087-H2090.
23. Medow MS, Glover JL, Stewart JM. Nitric oxide and prostaglandin inhibition during acetylcholine-mediated cutaneous vasodilation in humans. Microcirculation. 2008;15:569-579.
24. Jan YK, Struck BD, Foreman RD, et al. Wavelet analysis of sacral skin blood flow oscillations to assess soft tissue viability in older adults. Microvasc Res. 2009;78:162-168.
25. Tsuchida Y, Fukuda O, Kamata S. The correlation of skin blood flow with age, total cholesterol, hematocrit, blood pressure, and hemoglobin. Plast Reconstr Surg. 1991;88:844-850.
26. Tsuchida Y. The effect of aging and arteriosclerosis on human skin blood flow. J Dermatol Sci. 1993;5:175-181.
27. Macko RF, Gelber AC, Young BA, et al. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol. 2002;29:2565-2570.
28. Morgan-Rowe L, Nikitorowitcz J, Shiwen X, et al. Thrombospondin-1 in hypoxia conditionedmedia blocks the growth of human microvascular endothelial cells and is increased in systemic sclerosis tissues. Fibrogenesis Tissue Repair. 2011;4:13.
29. Chen Y, Leask A, Abraham DJ, et al. Thrombospondin 1 is a key mediator of transforming growth factor beta-mediated cell contractility in systemic sclerosis via amitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism. Fibrogenesis Tissue Repair. 2011;4:9.
30. Di Pietro LA, Nissen NN, Gamelli RL, et al. Thrombospondin 1 synthesis and function in wound repair. Am J Pathol. 1996;148:1851-1860.
31. Streit M, Velasco P, Riccardi L, et al. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J. 2000;19:3272-3282.
32. Isenberg JS, Qin Y, Maxhimer JB, et al. Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol. 2009;28:110-119.
33. Isenberg JS, Maxhimer JB, Powers P, et al. Treatment of liver ischemiareperfusion injury by limiting thrombospondin-1/CD47 signaling. Surgery. 2008;144:752-761.
34. Kaur S, Martin-Manso G, Pendrak ML, et al. Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J Biol Chem. 2010;285:38923-38932.
35. Isenberg JS, Shiva S, Gladwin M. Thrombospondin-1-CD47 blockade and exogenous nitrite enhance ischemic tissue survival, blood flow and angiogenesis via coupled NO-cGMP pathway activation. Nitric Oxide. 2009;21:52-62.
36. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med. 2002;6:1-12.
37. Chen H, Herndon ME, Lawler J. The cell biology of thrombospondin-1. Matrix Biol. 2000;19:597-614.
38. Olson BA, Day JR, Laping NJ. Age-related expression of renal thrombospondin 1 mRNA in F344 rats: resemblance to diabetes-induced expression in obese Zucker rats. Pharmacology. 1999;58:200-208.
39. Van Almen GC, Verhesen W, Van Leeuwen RE, et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell. 2011;10:769-779.
40. Bauer EM, Qin Y, Miller TW, et al. Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res. 2010;88:471-481.
41. Isenberg JS, Annis DS, Pendrak ML, et al. Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem. 2009;284:1116-1125.
42. Kellogg DL, Jr., Zhao JL, Wu Y, et al. Antagonism of soluble guanylyl cyclase attenuates cutaneous vasodilation during whole body heat stress and local warming in humans. J Appl Physiol. 2011;110:1406-1413.
43. Farrell DM, Bishop VS. Permissive role for nitric oxide in active thermoregulatory vasodilation in rabbit ear. Am J Physiol. 1995;269:H1613-H1618.
44. Brown H, Moppett IK, Mahajan RP. Transient hyperaemic response to assess vascular reactivity of skin: effect of locally iontophoresed acetylcholine, bradykinin, epinephrine and phenylephrine. Br J Anaesth. 2003;90:446-451.
45. Lutz J, Huwiler KG, Fedczyna T, et al. Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis. Clin Immunol. 2002;103:260-263.
46. Ignarro LJ, Cirino G, Casini A, et al. Nitric oxide as a signaling molecule in the vascular system: an overview. J Cardiovasc Pharmacol. 1999;34:879-886.
47. Ignarro LJ, Byrns RE, Wood KS. Endothelium-dependent modulation of cGMP levels and intrinsic smooth muscle tone in isolated bovine intrapulmonary artery and vein. Circ Res. 1987;60:82-92.
48. Tepelidis NT. Wound healing in the elderly. Clin Podiatr Med Surg. 1991;8:817-826.
49. Gosain A, Di Pietro LA. Aging and wound healing. World J Surg. 2004;28:321-326.
50. Isenberg JS, Romeo MJ, Abu-Asab M, et al. Increasing survival of ischemic tissue by targeting CD47. Circ Res. 2007;100:712-720.
51. Yano K, Oura H, Detmar M. Targeted overexpression of the angiogenesis inhibitor thrombospondin-1 in the epidermis of transgenic mice prevents ultraviolet-B-induced angiogenesis and cutaneous photo-damage. J Invest Dermatol. 2002;118:800-805.
52. Isenberg JS, Ridnour LA, Perruccio EM, et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A. 2005;102:13141-13146.
53. Isenberg JS, Pappan LK, Romeo MJ, et al. Blockade of thrombospondin-1- CD47 interactions prevents necrosis of full thickness skin grafts. Ann Surg. 2008;247:180-190.
54. Isenberg JS, Hyodo F, Matsumoto K, et al. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxidemediated vascular smooth muscle relaxation. Blood. 2007;109:1945-1952.
55. Bauer PM, Bauer EM, Rogers NM, et al. Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc Res. 2012;93:682-693.
56. Isenberg JS, Ridnour LA, Dimitry J, et al. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem. 2006;281:26069-26080.